WO2010133806A2 - Peptides marques et leur utilisation pour le dosage d'irap circulant - Google Patents
Peptides marques et leur utilisation pour le dosage d'irap circulant Download PDFInfo
- Publication number
- WO2010133806A2 WO2010133806A2 PCT/FR2010/050967 FR2010050967W WO2010133806A2 WO 2010133806 A2 WO2010133806 A2 WO 2010133806A2 FR 2010050967 W FR2010050967 W FR 2010050967W WO 2010133806 A2 WO2010133806 A2 WO 2010133806A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- modified
- peptide
- labeled
- irap
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
Definitions
- the protein IRAP (Insulin-Regulated Amino Peptidase, EC 3.4.11.3) also known as Placental Leucine Amino Peptidase (P-LAP) and Leucine-cystinyl aminopeptidase (L-CAP) is a transmembrane zinc metalloproteinase protein that exists under three isoforms (Swiss-Prot: Q9UIQ6: 1, 2 and 3, respectively represented by SEQ ID NO: 1 to 3).
- This enzyme degrades oxytocin (Naruki, M., et al., (1996) Peptides 17 (2), 257-261), vasopressin (Wallis, M. Cet (2007) Am J Physiol Endocrinol Metab 293 (4), E1092-1102), angiotensin II and III (Matsumoto, H., et al (2000) Eur J Biochem 267 (1), 46-52) as well as a series of other peptides (Albiston , AL, et al (2007) Pharmacol Ther 116 (3), 417-427). Serum concentrations of this aminopeptidase have never been reported in humans.
- P-LAP corresponds to the IRAP protein as well as to the angiotensin IV receptor (Keller, SR, et al., (1995) J Biol Chem 270 (40), 23612 Rogi, T., et al (1996) Biol Chem 271 (1), 56-61, Albiston, AL, et al (2001) J Biol Chem 276 (52), 48623-48626).
- International Application WO 2005/038462 discloses a reagent for the diagnosis and / or prognostic evaluation of carcinomas which comprises a polyclonal anti-P-LAP antibody, obtained by immunization with the entire P-LAP protein. Given the homology between the different aminopeptidases, the antibody is probably not specific for IRAP and will also recognize other aminopeptidases. It should therefore not be possible to diagnose a pathology specifically related to a change in the expression or plasma concentration of IRAP.
- IRAP indeed reduces sensitivity to anticancer drugs by inhibiting the expression of the triggering factor of apoptosis and increases the expression of the factor of inhibition of apoptosis.
- the extracellular domain of IRAP is cleaved by metalloproteases belonging probably to the ADAM family including ADAM9 and ADAM 12 (Ito, N., et al., (2004) Biochem Biophys Res Commun 314 (4), 1008-1013). and released into the bloodstream.
- ADAM9 MDC9
- MDC9 MDC9
- IRAP extracellular domain of IRAP
- a biological medium and a pathology concern severe preeclampsia as well as the threat of premature labor.
- the problem to be solved is even more complicated than that of the IRAP assay in its native form, partly because of the presence, in the serum or the plasma, of many elements. especially proteases liable to degrade the potential ligands of IRAP, and secondly the need to implement relatively heavy means.
- the purpose of the invention is to provide a reliable, specific and quantitative method for measuring the amount of circulating IRAP protein.
- Another object of the invention is to provide circulating IRAP ligands for its detection.
- the invention relates to a method for assaying the circulating extracellular portion of the IRAP protein ("insulin responsive aminopeptidase") comprising at least one step of quantitatively assaying said extracellular, secreted, purified part of IRAP, by means of at least one labeled peptide, said labeled peptide interacting specifically with said extracellular part of IRAP, said labeled peptide preferably being labeled with at least one radioactive isotope, said labeled peptide being an IRAP ligand, and in particular either a labeled substrate of the IRAP protein, an inhibitory peptide labeled with the IRAP protein, said peptide being optionally modified by the presence of at least one non-natural amino acid, and / or at least one ⁇ -homo amino acid, whether natural or not, subject to that said unmodified labeled peptide is different from angiotensin IV, and in particular that said unmodified labeled peptide is different from the SEQ ID
- the invention relates to a method for assaying the circulating extracellular portion of the protein IRAP ("insulin responsive aminopeptidase") comprising at least one step of quantitatively assaying said extracellular, secreted, purified part of IRAP by means of less a modified and labeled peptide, said labeled peptide interacting specifically with said extracellular part of IRAP, said peptide being modified by the presence of at least one non-natural amino acid, and / or at least one natural ⁇ -homo amino acid, or not, said labeled peptide being preferentially labeled with at least one radioactive isotope, provided that - said peptide is not an antibody and
- said modified peptide, labeled with a 125 I iodine atom is different from the Nle-Tyr-Ile-His-Pro-Phe sequence (SEQ ID No. 23).
- the present invention is based on the unexpected finding made by the inventors that labeled peptides allow effective quantitative detection of the extracellular portion of circulating IRAP.
- extracellular portion of the IRAP protein is defined in the invention as the domain, or chain of amino acids, of the IRAP protein that is exposed outside the cell when the IRAP protein is anchored. in the plasma membrane of cells.
- the "circulating extracellular portion" of the IRAP protein is defined in the invention as the extracellular portion of the IRAP protein as defined above which is no longer covalently bound to the transmembrane portion of the IRAP protein. This extracellular part is called circulating because, after its cleavage, it is found in the extracellular environment, and can be found in particular in plasma, serum, lymph, cerebrospinal fluid or urine.
- the extracellular part of circulating IRAP is called the extracellular part of secreted IRAP when it is found in the general circulation of the body, that is to say plasma, serum, lymph, cerebrospinal fluid. or urine.
- the terms "circulating extracellular portion of IRAP” and “extracellular portion of circulating IRAP” both refer to the extracellular domain of the IRAP protein which is no longer associated with the membrane portion of IRAP, and therefore no longer associated with the cell membrane.
- the IRAP protein that is the subject of the invention is represented by the amino acid sequence SEQ ID No. 1.
- peptide any peptide chain corresponding to a covalent succession of at least two amino acids, or amino acid derivatives, linked by an amide function (-CO-NH-), said amino acids being natural or not and said amino acid derivatives being natural or non-naturally occurring amino acid derivatives.
- labeled peptide in the invention a peptide as defined above having a molecule or an atom allowing its detection other than by conventional detection methods of proteins or peptides, that is to say -describe methods other than immunological methods.
- the labeled peptides according to the invention can be coupled to either fluorescent molecules (cyanines, coumarins, rhodamines, xanthenes, quantum dots (nanocrystals of semiconductor materials), etc.), or can contain at least one, one or more radioactive atom (s), said radioactive atom being also called radioactive isotope.
- radioactive isotopes which may be used in the invention, mention may be made of tritium ( 3 H), carbon 14 ( 14 C), iodine 131 ( 131 I) and iodine 125 ( 125 I). or phosphate 32 or 33 ( 32 P OR 33 P).
- the peptides according to the invention are labeled with one or more 125 I ( 125 I) atoms, preferably with a single 125 I ( 125 I) atom.
- the radioactive isotopes are capable of disintegrating and emitting particles in the form of radiation, said radiation being measurable by means for example of scintillation counters or not, and said proportional radiation being the amount of isotope.
- the quantification of the extracellular portion of IRAP is performed from the extracellular portion of IRAP that has been purified.
- Methods for purifying the circulating IRAP protein may be any method of purifying proteins known to those skilled in the art.
- a preferred, but not limiting, method is an immunological method and in particular the immunoprecipitation or immunocapture of the circulating IRAP protein, by means of a specific antibody directed against the extracellular portion of the IRAP protein.
- the immunological immunocapture method of the extracellular portion of circulating IRAP is described in the examples.
- the term "quantitative assay” means the action of precisely determining the amount of circulating IRAP protein contained in a biological sample of an individual or an animal.
- said labeled peptide interacting specifically with said extracellular portion of IRAP used in the invention mean that at least one labeled peptide according to the invention and the purified extracellular portion of circulating IRAP form a complex of high affinity.
- the order of magnitude of the affinity between said peptides and said circulating extracellular portion of IRAP is between about 10 -10 M to 10 -5 M, preferably between about 0.1 nM and about 100 nM.
- the terms are used to include the measurement variability of said affinity, said variation being generally from 5 to 10% error on the measurement.
- the intensity of the interaction is measured for example as described in Lukaszuk et al. (J. Med Chem 2008, 51, pp: 2291-2296).
- the interaction is said to be specific, which means that the labeled peptide according to the invention is capable of forming a complex with the circulating extracellular portion of the IRAP protein, but said labeled peptide is not capable of forming a complex of the same affinity at the same concentrations with another protein having an amino acid sequence different from the amino acid sequence of said extracellular portion of IRAP.
- the labeled peptide of the invention is an IRAP ligand, and in particular is a labeled substrate of the IRAP protein, or an inhibitory peptide labeled with the IRAP protein, or any peptide whose affinity for the extracellular portion of circulating IRAP. is less than or equal to 10 ⁇ M ( ⁇ 10 nM).
- the peptide defined above can be modified by the presence of at least one non-natural amino acid, and / or at least one ⁇ -homo amino acid, natural or non-natural.
- non-natural amino acid is meant in the invention amino acids that are not found naturally in proteins when synthesized in a living organism, or acellular system using the natural machinery of protein synthesis (mRNA , TRNA, ribosomes ).
- the natural amino acids are the 20 amino acids known to those skilled in the art and whose correspondence with the triplets of nucleotides is given by the genetic code.
- the non-natural amino acids used in the invention include, but are not limited to, amino acids derived from leucine such as cycloleucine (CIe), norleucine (Nie) or tert-leucine (ITe).
- ⁇ -homo amino acid it is defined in the invention an amino acid having an additional carbon.
- the amino acids correspond to 2- (or ⁇ ) amino 2- [side chain (R)] acetic acids
- the ⁇ homo amino acids correspond to 3 - (or ⁇ homo) 2 - [Side chain (R)] amino propanoic acids ( ⁇ 2 homo amino acid), or 3 - (or ⁇ homo) 3- [Side chain (R)] amino propanoic acids ( ⁇ 3 homo amino acid).
- the formulas of the ⁇ 2 homo amino acid and the ⁇ 3 homo amino acid are as follows:
- the invention does not relate to the use of an unmodified labeled peptide which would be angiotensin IV, and in particular human Angiotensin IV of sequence SEQ ID NO: 21
- the invention does not relate to the use of a modified peptide, labeled with an Iodine 125 I atom, corresponding to Angiotensin IV or valine in position 1 is replaced by a Nie and represented by the sequence SEQ ID NO : 23 (Nle-Tyr-Isle-His-Pro-Phe).
- the specific sequences will reveal natural amino acids, non-natural amino acids, and ⁇ 2 or ⁇ 3 derivatives of said natural amino acids or not.
- the labeling does not appear in the sequence, for which reason the labeled peptide of sequence X will be represented by the sequence SEQ ID NO X unlabeled, and the type of labeling is specified.
- the peptide X labeled with radioactive iodine will be indicated as follows: peptide of sequence SEQ ID NO X labeled with iodine 125 I.
- the subject of the invention is a method for assaying the circulating extracellular portion of IRAP as defined above, wherein said labeled peptide is not modified, provided that said unmodified labeled peptide is different from the angiotensin IV, and in particular that said unmodified labeled peptide is different from the sequence SEQ ID No. 21 (VaI-Tyr-Ile-His-Pro-Phe).
- These unmodified labeled peptides have the advantage of being similar or equivalent to the unlabeled peptides, and therefore of having a high affinity for the extracellular portion of the circulating IRAP protein.
- the invention relates to a method for assaying the circulating extracellular portion of IRAP as defined above, wherein said labeled peptide is modified by the presence of at least one non-natural amino acid, and / or at least one ⁇ -homo amino acid, natural or non-natural, said modified labeled peptide interacting specifically with said extracellular part of IRAP, provided that said modified peptide, labeled with an iodine atom 125 I, is different from the Nle-Tyr-Ile-His-Pro-Phe sequence (SEQ ID No. 23).
- modified labeled peptides have the advantage of having a high affinity for the extracellular portion of the circulating IRAP protein, and of having a high stability, especially in a sample containing numerous proteases or peptidases.
- the stability of the peptides according to the invention may in particular be measured by evaluating the inhibitory properties exerted by said peptides on the aminopeptidase activity of IRAP. This measure of stability is illustrated in the examples.
- the invention also relates, in an advantageous embodiment, to a method for assaying the circulating extracellular portion of IRAP as defined above, comprising at least:
- the method according to the invention comprises at least one step of purifying the extracellular portion of IRAP in a biological sample. This purification step is followed by a step of quantification of said extracellular portion of IRAP purified in the previous step. This second step is implemented using at least one modified peptide as defined above.
- the purification of the circulating extracellular portion of IRAP can be carried out by an immunological method, that is to say a method using an antibody directed against the IRAP protein, in particular immunoprecipitation or immunocapture.
- This method is specific when it uses a specific antibody that recognizes only the extracellular portion of the IRAP protein, and makes it possible to obtain an extracellular portion of the pure IRAP protein.
- the degree of contamination by other proteins can be evaluated by a conventional method of protein separation (SDS-PAGE) coupled with a protein detection method (silver staining, colloidal blue staining, etc.). methods known to those skilled in the art.
- Immunoprecipitation or immunocapture allows a purification to a very widely acceptable degree (> 90%), and in particular makes it possible to isolate a protein from its environment, for example contaminating proteases.
- the invention relates, in another advantageous embodiment, to a method for assaying the circulating extracellular portion of IRAP as defined above, in which the said inhibitory peptide labeled with the IRAP protein is modified and is chosen from: Angiotensin IV labeled and modified and the labeled and modified LVV-hemorphin-7, or said labeled substrate of the IRAP protein is modified and is selected from: the labeled and modified [Arg] vasopressin, the modified and modified oxytocin, MeWLeu-enkephaline labeled and modified, labeled and modified Somatostatin, labeled and modified CCK-8, labeled and modified Neurokinin A, labeled and modified Neuromedin B, labeled and modified Lys-bradykinin and modified and modified modified modified Dynorphin A.
- the modified labeled peptides that may be used in the invention correspond to either substrates of the IRAP protein or to peptide inhibitors of the IRAP protein.
- the inhibitory peptides are chosen from LVV-hemorphin-7 or angiotensin IV. These inhibitory peptides are modified and labeled.
- the IRAP protein is a protease, so it is able to cleave proteins, said proteins being IRAP substrates.
- the aforementioned proteins as IRAP substrate are therefore proteins susceptible to be cleaved by IRAP.
- the catalytic activity of IRAP can be blocked by compounds known as inhibitors.
- the inhibitors bind to the active site of an enzyme, are not metabolized by said enzyme, and prevent it from accessing its substrates. This kind of inhibition is a competitive inhibition.
- LVV-hemorphin-7 or angiotensin IV are peptides that inhibit IRAP activity.
- the invention relates to a method for assaying the circulating extracellular portion of IRAP as defined above, wherein said purification of the circulating portion of the IRAP protein is carried out by means of at least an antibody specific for said extracellular portion of IRAP, in particular by immunoprecipitation or immunocapture.
- the invention proposes to use an antibody specifically recognizing the extracellular portion of IRAP, and not recognizing the transmembrane or intracellular portion of said IRAP protein.
- This purification method may be an immunoprecipitation where an antibody specific for the extracellular portion of IRAP is attached to sugar polymer beads (agarose, sepharose).
- the purification method may also be an immunocapture in the context of an ELISA or an immunomagnetic radio test (IRMA) in which the said specific antibodies are fixed on a support, in particular the wall of a tube, and immobilize IRAP on this support. this.
- IRAP extracellular concentration of IRAP must be measured at least one of the following products: - chelators of cations such as: EDTA, EGTA, 1,10-orthophenantroline, dimercaprol, lipoic acid, BAPTA (1,2-bis (o-aminophenoxy) ethane-N, N, N ', N'-tetraacetic acid), DTPA (diethylene acid) triamine pentaacetic), DMPS (2,3-dimercapto-1-propanesulfonic acid), DMSA (dimercaptosuccinic acid), penicillamine, deferroxamine, sulfosalicylic acid, citric acid, oxalic acid, tartaric acid, N 5 N-Dimethyldecylamine N-oxide, acid nitrilotriacetic acid, pyromellitic acid,
- - chelators of cations such as: EDTA, EGTA, 1,10-
- inhibitors of proteases and peptidases such as: AEBSF (4- (2-Aminoethyl) benzenesulfonyl fluoride hydrochloride), 6-aminohexanoic acid, antipain, aprotinin, benzamidine dine, bestatin, chymostatin, E-64, leupeptin, pepstatin, phosphoramidon, trypsin inhibitor, diisopropyl fluorophosphate, PMSF, p-chloromercuribenzoic acid, diethyl pyrocarbonate, 2-Mercaptoethylamine, Apstatin, Phebestin, Bromoenol lactone, Ecotin (acid 1, 4 , 5,6-tetrahydro-2-methyl-4-pyrimidine carboxilic acid), N-acetyl-eglin C, Gabexate mesylate, N-Tosyl-L-phenylalanine chloromethyl ketone, Na-T-
- the invention relates to a method for assaying the circulating extracellular portion of IRAP defined above, wherein said IRAP protein is represented by
- the homologs of the IRAP protein correspond to proteins having a sequence homologous to the sequence SEQ ID No. 1 but having amino acid substitutions.
- the isoforms of the IRAP protein defined in the invention correspond to products of the alternative splicing of the product of the gene encoding the IRAP protein, so that the protein
- the resulting isoforms of the invention correspond to truncated proteins in the aminoterminal portion of several amino acids.
- Another advantageous embodiment of the invention relates to an assay method defined above, where
- Said variants of the IRAP protein have an amino acid sequence chosen from the sequences SEQ ID NO 4 to SEQ ID NO 7, and
- Said isoforms of the IRAP protein have an amino acid sequence selected from the sequences SEQ ID NO 8 to SEQ ID NO 15.
- the invention relates to an assay method as defined above, wherein said circulating extracellular portion of the IRAP protein has an amino acid sequence represented by the sequences chosen from the following sequences: SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
- Another advantageous embodiment of the invention relates to a previously defined assay method, wherein said labeled modified peptide is labeled with at least one tritium atom or at least one 125 I iodine atom, that is to say an iodine atom or more, preferably a single 125 I iodine atom.
- the invention also relates in a preferred embodiment to a previously defined assay method, wherein said modified modified peptide is represented by the following general formula (III):
- R 1 is chosen from: a group -CH (CH 3 ) 2 , a group -CH 2 -CH (CH 3 ) 2, a group -CH (CH 3 ) -CH 2 -CH 3 , a group - (CH 2 ) 3 -CH 3 and a group C (CH 3 ) 3 , and R 1 'is a hydrogen atom, or R 1 and R 1' together with the carbon which carry them a cyclopentyl, where (R 2 , R 2 ') are such that: if R2 is chosen from: a group -CH 2 -CH (CH 3 ) 2 , a group -CH (CH 3 ) -CH 2 -CH 3 , a group - (CH 2 ) 3 -CH 3 and a group C (CH 3 ) 3 , R 2 'is a hydrogen atom, or
- R2 and R2 ' together with the carbon which carries them a cyclopentyl, the pairs (R 1 , R 1 ') and (R 2 , R 2 ') being chosen independently of each other, where A is selected from the following groups
- said modified modified peptide being in the form of a racemate, any of its enantiomers, or any of the various tautomers corresponding to said racemates and enantiomers,
- A is represented by the formula IHa and if a, b, c, d, e, f, g, h, i and j are 0,
- modified modified peptide corresponds to one of the following three general formulas:
- the invention also relates in a preferred embodiment to a previously defined assay method, wherein said modified modified peptide is represented by the following general formula (I):
- a, b, c, d, e, f, g, h, i, and j may be 0 or 1, such that (a + b) ⁇ l, (c + d) ⁇ l, (e + f) ⁇ l, (g + h) ⁇ l and (i, j) ⁇ l, (a, b), (c, d), (e, f), (g, h) and (i, j ) being independent of one another, where (Ri, Ri ') are such that:
- R 1 is chosen from: a group -CH (CH 3 ) 2 , a group -CH 2 -CH (CH 3 ) 2, a group -CH (CH 3 ) -CH 2 -CH 3 , a group - (CH 2 ) 3 -CH 3 and a group C (CH 3 ) 3 , and R 1 'is a hydrogen atom, or R 1 and R 1' together with the carbon which carry them a cyclopentyl, where (R 2 , R 2 ') are such that: if R2 is chosen from: a group -CH 2 -CH (CH 3 ) 2 , a group -CH (CH 3 ) -CH 2 -CH 3 , a group - (CH 2 ) 3 -CH 3 and a group C (CH 3 ) 3 , R 2 'is a hydrogen atom, or
- the invention relates to a previously defined assay method, in which the labeled modified peptide is chosen from the following peptides:
- the invention also relates to an assay method as defined above, wherein said labeled and modified peptide consists of the following sequence:
- X1 can be a Valine (Val), a Leucine (Leu), an Isoleucine (Ile), a Norleucine (Nie), a Cycloleucine (CIe) or a tert-leucine (TIe), or a derivative ⁇ 2 or ⁇ 3 of one of these amino acids,
- X2 may be a tyrosine, or a ⁇ 2 or ⁇ 3 derivative of tyrosine,
- X3 can be a Leucine (Leu), an Isoleucine (Ile), a Norleucine (Nie), a Cycloleucine (CIe) or a tert-leucine (TIe), or a derivative ⁇ 2 or ⁇ 3 of one of these amino acids ,
- X4 may be a proline or a ⁇ 2 or ⁇ 3 derivative of proline
- X5 may be a phenylalanine, or a ⁇ 2 or ⁇ 3 derivative of phenylalanine, and (His-X4) may be
- At least one of the amino acids X1 to X5 is a non-natural amino acid, and / or a ⁇ -homo amino acid, natural or otherwise provided that the sequence SEQ ID NO 22 labeled with an iodine atom 125 I is different from the Nle-Tyr-Ile-His-Pro-Phe sequence (SEQ ID NO 23).
- the invention relates to an aforementioned assay method, wherein said labeled and modified peptide consists of the following sequence: X1-X2-X3-His-X4-X5 (SEQ ID NO 22) where
- X1 can be a Valine (Val), a Leucine (Leu), an Isoleucine (Ile), a Norleucine (Nie), a Cycloleucine (CIe) or a tert-leucine (TIe), or a derivative ⁇ 2 or ⁇ 3 of one of these amino acids
- X2 may be a tyrosine, or a ⁇ 2 or ⁇ 3 derivative of tyrosine,
- X3 can be a Leucine (Leu), an Isoleucine (Ile), a Norleucine (Nie), a Cycloleucine (CIe) or a tert-leucine (TIe), or a derivative ⁇ 2 or ⁇ 3 of one of these amino acids ,
- X4 can be proline or a ⁇ 2 or ⁇ 3 derivative of proline
- X5 may be a phenylalanine, or a ⁇ 2 or ⁇ 3 derivative of phenylalanine, at least one of amino acids X 1 to X 5 being a non-natural amino acid, and / or a ⁇ -homo amino acid, natural or non-natural. provided that the sequence SEQ ID No. 22 labeled with a 125 I iodine atom is different from the Nle-Tyr-Ile-His-Pro-Phe sequence (SEQ ID No. 23).
- the modified modified peptide consisting of the amino acid sequence SEQ ID No. 22 corresponds to the peptide of general formula (I) defined above, in which all the amino acids are in an L configuration according to the L nomenclature. / D known to those skilled in the art.
- An advantageous embodiment of the invention relates to a previously defined assay method, wherein said labeled and modified peptide consists of the following sequence:
- Xl-X2-X3-His-X4 -X5 (SEQ ID No. 22) and wherein at least one of amino acids X1 to X5 is a ⁇ -homo amino acid, natural or not.
- at least one of the amino acids X1, or X2, or X3, or X4 or X4 or X5 corresponds to an amino acid chosen from: ⁇ 2homo valine, ⁇ 3homo valine, ⁇ 2homo leucine, ⁇ 3homo leucine, ⁇ 2homo isoleucine, ⁇ 3homo isoleucine, ⁇ 2homo tyrosine, ⁇ 3homo tyrosine, ⁇ 2homo proline, ⁇ 3homo proline, ⁇ 2homo phenylalanine, ⁇ 3homo phenylalanine, ⁇ 2 homo norleucine, ⁇ 3 homo norleucine, ⁇ 2 homo tertleucine, ⁇ 3 homo tertleu
- the invention relates to a previously defined assay method, wherein said labeled modified peptide is labeled
- At least one 125 I iodine atom on tyrosine X 2 preferably one single 125 I iodine atom, in particular on the phenyl group, or
- the modified labeled peptide of the invention is labeled with an iodine atom 125
- said peptide has at least one 125 I atom, or two 125 I atoms, in the meta position on the benzyl ring of tyrosine, or in the meta position on the benzyl ring of the ⁇ 2 homo tyrosine or ⁇ 3 homo tyrosine derivatives.
- the peptide is labeled with a single 125 I iodine atom.
- Another advantageous embodiment of the invention relates to a previously defined assay method, wherein said labeled modified peptide is selected from the following peptides: ⁇ 2 hVal-Tyr-Ile-His-Pro-Phe- (SEQ ID NO 24 ), of formula:
- the above peptides have a high affinity for the circulating extracellular portion of IRAP, are stable, and easily detectable by counting the radioactivity emitted by 125 I iodine.
- the invention relates to a previously defined assay method, wherein said labeled modified peptide is selected from the following peptides: - ⁇ 2hVal-Tyr-Ile-His-Pro-Phe- (SEQ ID NO 24),
- the above peptides have a high affinity for the circulating extracellular portion of IRAP, are stable, and easily detectable by counting the radioactivity emitted by tritium H.
- Another advantageous embodiment of the invention relates to an assay method defined above, comprising
- Another advantageous embodiment of the invention relates to a previously defined assay method, comprising: a step of purifying said circulating extracellular portion of IRAP, and
- the invention also relates to a labeled modified peptide represented by the following general formula (III):
- R 1 is chosen from: a group -CH (CH 3 ) 2 , a group -CH 2 -CH (CH 3 ) 2, a group -CH (CH 3 ) -CH 2 -CH 3 , a group - (CH 2 ) 3 -CH 3 and a group C (CH 3 ) 3 , and R 1 'is a hydrogen atom, or R 1 and R 1' together with the carbon which carry them a cyclopentyl, where (R 2 , R 2 ') are such that: if R2 is chosen from: a group -CH 2 -CH (CH 3 ) 2 , a group -CH (CH 3 ) -CH 2 -CH 3 , a group - (CH 2 ) 3 -CH 3 and a group C (CH 3 ) 3 , R 2 'is a hydrogen atom, or
- R2 and R2 ' together with the carbon which carries them a cyclopentyl, the pairs (R 1 , R 1 ') and (R 2 , R 2 ') being chosen independently of each other, where A is selected from the following groups
- said modified modified peptide being in the form of a racemate, any of its enantiomers, or any of the various tautomers corresponding to said racemates and enantiomers,
- A is represented by the formula IHa and if a, b, c, d, e, f, g, h, i and j are 0,
- the invention also relates to a labeled modified peptide represented by the following general formula (I):
- said peptide possibly modified by the presence of at least one non-natural amino acid, and / or at least one ⁇ -homo amino acid, natural or not, where a, b, c, d, e, f, g, h, i and j may be equal to 0 or 1, such that (a + b) ⁇ l, (c + d) ⁇ l, (e + f) ⁇ l, (g + h) ⁇ l and (i, j) ⁇ 1, (a, b), (c, d), (e, f), (g, h) and (i, j) being independent of each other, where (Ri, Ri ') are such than :
- R1 is chosen from: a group -CH (CH 3 ) 2 , a group -CH 2 -CH (CH 3 ) 2i a group -CH (CH 3 ) -CH 2 -CH 3 , a group - (CH 2 ) 3 -CH 3 and a group C (CH 3 ) 3 , and R 1 'is a hydrogen atom, or - R 1 and R 1' together with the carbon which bears them a cyclopentyl, where (R 2 , R 2 ') are such as : - if R2 is chosen from: a group -CH 2 -CH (CH 3 ) 2, a group -CH (CH 3 ) -CH 2 -CH 3 , a group - (CH 2 ) 3 -CH 3 and a group C (CH 3 ) 3 , R2 'is a hydrogen atom, or
- An advantageous embodiment of the invention relates to a labeled peptide as defined above, represented by the general formula Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, II, Im, In, Io, IHd or IHe as defined above.
- the invention also relates, in an advantageous embodiment, to a labeled and modified peptide consisting of the following sequence:
- X1 can be a Valine (Val), a Leucine (Leu), an Isoleucine (Ile), a Norleucine (Nie), a Cycloleucine (CIe) or a tert-leucine (TIe), or a derivative ⁇ 2 or ⁇ 3 of one of these amino acids,
- X2 may be a tyrosine, or a ⁇ 2 or ⁇ 3 derivative of tyrosine,
- X3 can be a Leucine (Leu), an Isoleucine (Ile), a Norleucine (Nie), a Cycloleucine (CIe) or a tert-leucine (TIe), or a derivative ⁇ 2 or ⁇ 3 of one of these amino acids
- X4 may be a proline or a ⁇ 2 or ⁇ 3 derivative of proline
- X5 may be a phenylalanine, or a ⁇ 2 or ⁇ 3 derivative of phenylalanine, and (His-X4) may be an aba-gly of formula lia or
- At least one of the amino acids X1 to X5 is a non-natural amino acid, and / or a ⁇ -homo amino acid, natural or otherwise provided that the sequence SEQ ID NO 22 labeled with an iodine atom 125 I is different from the Nle-Tyr-Ile-His-Pro-Phe sequence (SEQ ID NO 23).
- the invention relates to the aforementioned modified unlabeled peptides, in particular the peptides of formulas IbbI and IIIc that follow:
- An advantageous aspect of the invention relates to a labeled peptide defined above, said peptide being labeled with at least one radioactive isotope consisting of the following sequence: X1-X2-X3-His-X4-X5 (SEQ ID NO. 22) ) said modified peptide, where
- X1 can be Valine (Val), Leucine (Leu), Isoleucine (Ile), or an unnatural amino acid derived from leucine, in particular Norleucine (Nie), Cyclo leucine (CIe) or tert- leucine (TIe), or a ⁇ 2 or ⁇ 3 derivative of either these natural or unnatural amino acids,
- X2 may be a tyrosine, or a ⁇ 2 or ⁇ 3 derivative of tyrosine,
- X3 may be Leucine (Leu), Isoleucine (Ile), or an unnatural amino acid derived from leucine, in particular Norleucine (Nie), Cycloleucine (CIe) or tert-leucine (TiE), or a derivative thereof ⁇ 2 or ⁇ 3 of one of these natural or unnatural amino acids
- X4 can be proline or a ⁇ 2 or ⁇ 3 derivative of proline
- X5 can be a phenylalanine, or a ⁇ 2 or ⁇ 3 derivative of phenylalanine and provided that said unmodified labeled peptide is different from angiotensin IV, and in particular that said unmodified labeled peptide is different from SEQ ID NO.
- the invention relates to a modified modified peptide defined above, consisting of the following sequence:
- X1-X2-X3-His-X4-X5 SEQ ID NO 22
- said peptide being modified such that at least one amino acid X1 to X5 is a ⁇ -homo amino acid, natural or not.
- Another advantageous aspect of the invention relates to a modified modified peptide defined above, said modified labeled peptide being labeled:
- the invention relates to a modified modified peptide mentioned above, wherein said modified labeled peptide is selected from the following peptides:
- the invention relates to a modified modified peptide mentioned above, wherein said modified labeled peptide is selected from the following peptides:
- FIGS. 1A-Q represent the absorption spectra at 215 nm of elutions on reverse phase HPLC in the presence of water / acetonitrile solvent, the mobile phase containing 0.1% of TFA.
- the standard gradient corresponds to a 20 min migration from 3% to 97% acetonitrile, at a rate of 1 mL / min.
- FIG. 1A represents the UV absorption spectrum as a function of time of the peptide H- ⁇ 3hVal-Tyr-Ile-His-Pro-Phe-OH.
- FIG. 1B shows the UV absorption spectrum as a function of time of the peptide H-VaI- ⁇ 3hTyr-Ile-His-Pro-Phe-OH.
- FIG. 1C represents the UV absorption spectrum as a function of time of the H-VaI-peptide.
- FIG. 1D shows the UV absorption spectrum as a function of time of the H-VaI-peptide.
- FIG. 1E represents the UV absorption spectrum as a function of time of the H-VaI-peptide.
- Figure IF shows the UV absorption spectrum as a function of time of the first diastereoisomer of the peptide H- ⁇ 2hVal-Tyr-Ile-His-Pro-Phe-OH.
- FIG. 1G shows the UV absorption spectrum as a function of time of the peptide of the second diastereoisomer of the peptide H- ⁇ 2hVal-Tyr-Ile-His-Pro-Phe-OH.
- FIG. 1H shows the UV absorption spectrum as a function of time of the mixture of the H-Val- ⁇ 2hTyr-Ile-His-Pro-Phe-OH peptide racemates.
- FIG. II represents the UV absorption spectrum as a function of time of the first diastereoisomer of the peptide H-Val-Tyr- ⁇ 2hLeu-His-Pro-Phe-OH
- FIG. 1J represents the UV absorption spectrum as a function of time of the mixture of the H-Val-Tyr- ⁇ 2hLeu-His-Pro-Phe-OH peptide racemates
- FIG. 1K represents the UV absorption spectrum as a function of time of the peptide H-VaI-Tyr-Ile-His- ⁇ 2hPro-Phe-OH
- FIG. 11 represents the UV absorption spectrum as a function of time of the mixture of the H-Val-Tyr-Ile-His-Pro- ⁇ 2hPhe-OH peptide racemates.
- FIG. 1I shows the UV absorption spectrum as a function of time of the peptide H- ⁇ 2hVal-Tyr-Ile-His-Pro- ⁇ 3hPhe-OH.
- FIG. 1N represents the UV absorption spectrum as a function of time of the peptide.
- FIG. 10 represents the UV absorption spectrum as a function of time of the mixture of the H- ⁇ 2hNle-Tyr-Ile-His-Pro-Phe-OH peptide racemates.
- FIG. 1P represents the UV absorption spectrum as a function of time of the mixture of the H- ⁇ 2HLeu-Tyr-Ile-His-Pro-Phe-OH peptide racemates.
- FIG. 10 represents the UV absorption spectrum as a function of time of the mixture of the H- ⁇ 2hLeu-Tyr-Ile-His-Pro- ⁇ 3hPhe-OH peptide racemates
- FIGS. 2A-Q show the absorption spectra at 215 nm of elutions on reverse phase HPLC in the presence of water / methanol solvent, the mobile phase containing 0.1% of TFA.
- the standard gradient corresponds to a 20 min migration from 3% to 97% methanol, at a rate of 1 mL / min.
- FIG. 2A represents the UV absorption spectrum as a function of time of the H- ⁇ 3hVal-Tyr-Ile-His-Pro-Phe-OH peptide.
- FIG. 2B represents the UV absorption spectrum as a function of time of the peptide H-VaI- ⁇ 3hTyr-Ile-His-Pro-Phe-OH.
- FIG. 2C represents the UV absorption spectrum as a function of time of the H-VaI-peptide.
- FIG. 2D represents the UV absorption spectrum as a function of time of the H-VaI-peptide.
- FIG. 2E represents the UV absorption spectrum as a function of time of the peptide H-VaI-Tyr-Ile-His-Pro- ⁇ 3hPhe-OH.
- FIG. 2F represents the UV absorption spectrum as a function of time of the first diastereoisomer of the peptide H- ⁇ 2hVal-Tyr-Ile-His-Pro-Phe-OH.
- FIG. 2G represents the UV absorption spectrum as a function of time of the peptide of the second diastereoisomer of the peptide H- ⁇ 2hVal-Tyr-Ile-His-Pro-Phe-OH.
- FIG. 2H shows the UV absorption spectrum as a function of time of the mixture of the H-Val- ⁇ 2hTyr-Ile-His-Pro-Phe-OH peptide racemates.
- FIG. 21 represents the UV absorption spectrum as a function of time of the first diastereoisomer of the H-Val-Tyr- ⁇ 2hLeu-His-Pro-Phe-OH peptide;
- FIG. 2 J represents the UV absorption spectrum as a function of time of the mixture of the H-Val-Tyr- ⁇ 2hLeu-His-Pro-Phe-OH peptide racemates.
- FIG. 2K represents the UV absorption spectrum as a function of time of the H-VaI-peptide.
- FIG. 2L shows the UV absorption spectrum as a function of time of the mixture of the H-Val-Tyr-Ile-His-Pro- ⁇ 2hPhe-OH peptide racemates.
- FIG. 2M represents the UV absorption spectrum as a function of time of the peptide H- ⁇ 2hVal-Tyr-Ile-His-Pro- ⁇ 3hPhe-OH
- FIG. 2N represents the UV absorption spectrum as a function of time of the peptide
- FIG. 20 represents the UV absorption spectrum as a function of time of the mixture of the H- ⁇ 2hNle-Tyr-Ile-His-Pro-Phe-OH peptide racemates.
- FIG. 2P represents the UV absorption spectrum as a function of mixing time of the H- ⁇ 2hLeu-Tyr-Ile-His-Pro-Phe-OH peptide racemates
- FIG. 20 shows the UV absorption spectrum as a function of time of the mixture of the H- ⁇ 2hLeu-Tyr-Ile-His-Pro- ⁇ 3hPhe-OH peptide racemates
- Figures 3A-D show HPLC profiles of iodination of peptides # 6, 11, and 17 and angiotensin IV.
- the x-axis represents the retention time in minutes, and the y-axis represents the intensity expressed in mV / I *.
- FIG. 3A represents the profile of the peptide of angiotensin IV
- FIG. 3B represents the profile of ligand 6
- FIG. 3C represents the profile of ligand 11
- Figure 3D shows the profile of ligand 16.
- Figure 4 depicts HPLC profiles of iodination of peptide No. 17 mono iodine.
- the x-axis represents the retention time in minutes, and the y-axis represents the intensity expressed in mV / I *.
- Figure 5 shows the binding of angiotensin IV and peptide derivatives (ligands 6,11 and 17) to the recombinant IRAP-His protein.
- the abscissa axis represents the amount of recombinant IRAP expressed in ⁇ g / mL, the ordinate axis represents the radioactivity of iodine 125 expressed in B / Bmax.
- the peptides were synthesized on a Boc-Phe Merrified Resin (0.57 mmol / g), a Wang Fmoc-Phe resin (0.76 mmol / g) or a 2-chlorotrityl chloride resin (1.5 mmol / g). ).
- the side chain protection groups were Tyr (t-Bu), ⁇ 3-hTyr (t-Bu), and His (Trt) for Fmoc synthesis, and Tyr (2,6-di-Cl-Bzl) and His ( Tos) for Boc synthesis.
- the Fmoc protection groups were removed with a solution of 20% piperidine in dimethyl formamide (DMF) (2 x 5 min), and the cleavage of the Boc protection groups was carried out in a solution of 50% trifluoroacetic acid ( TFA) in dichloromethane (DCM) (2 x 10 min) and a solution of 10% triethylamine (TEA) in DCM (2 x 5 min) was used for the neutralization.
- TFA trifluoroacetic acid
- DCM dichloromethane
- TEA triethylamine
- the amino acid coupling was carried out in DMF / DCM (Iv / Iv) using O- (Benzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium tetrafluoroborate (TBTU) (3 equivalents) and diisopropylethylamine (DIPEA) (6 equivalents).
- TBTU Benzotriazol-1-yl
- DIPEA diisopropylethylamine
- the 3 eq of amino acids (relative to the resin) and 6 eq of DIPEA (relative to the resin) were dissolved in CH 2 Cl 2 (10 ml per 1 g of resin), containing, if necessary a small amount of DMF to facilitate the solubility of the amino acid.
- the 2-chlorotritilchloride resin was pre-stabilized in CH 2 Cl 2 for 1 h, and after adding the mixture the resin was mixed for 30-120 min. Later, the resin was washed three times with CH 2 Cl 2 / MeOH / DIPEA (17: 2: 1), then twice with DMF and three times with CH 2 Cl 2 .
- the amino-Boc acid was dissolved in EtOH (2 mL / mmol) and at 0. 5 mL / mmol, the pH was adjusted to 7 with 2M aqueous CS2CO3 solution. The solution was evaporated by drying, the residues were evaporated twice with dioxane.
- the Merrified resin was pre-stabilized in CH 2 Cl 2 for 1 h and washed with DMF. The cesium salt of amino acid (1.2 eq) in DMF was added to the resin, and the whole heated at 50 0 C overnight. At the end of the reaction, the resin was washed three times in DMF, three times in DMF / water (1: 1), three times in DMF, three times in CH 2 Cl 2 , and three times in MeOH.
- the colorimetric test corresponds to a Kaiser test. This test consists of 3 solutions: A: 5 g of ninhydrin in 100 ml of n-BuOH; B: 80 g of phenol in 20 ml of n-BuOH; C: 2 mL 0.001 M aqueous KCN in 98 mL of pyridine.
- Some resin beads are placed in a test tube. 3 drops of each of the solutions are added and the tube is heated at 100 ° C. for 5 minutes. When the resin or solution is colorless or yellowish, the result is negative. A blue color indicates the presence of a primary amine, and a brown / red color indicates the presence of a secondary amine.
- the peptides were cleaved from the resin by treatment with a TFA / H 2 O / triethylsylan (TES) mixture (95: 2.5: 2.5) for 2 h, either with HF hydrofluoric acid, or a TF A / trifluoromethanesulphonic acid mixture ( TFMSA) / TES (20: 2: 3) in the case of a Merrif ⁇ eld resin.
- TES triethylsylan
- TFMSA trifluoromethanesulphonic acid mixture
- TES triethylsylan
- the peptides were purified by reverse phase HPLC on a C18 Supelco Disco-BIO Wide Pore column. Each peptide was at least 98% pure after thin layer chromatography (TLC) and reversed phase HPLC analysis in water / acetonitrile solvent (FIGS. IA-IQ), or in a water / methanol solvent (FIGS. 2A-2Q). ). Molecular weights were confirmed by mass spectrometry-electrospay / ionization (ESI-MS).
- M cal corresponds to the predicted mass
- ESI MS corresponds to the mass obtained by mass spectrometry
- R corresponds to the yield in percent relative to the crude peptides
- Time Retl corresponds to the time at the time of elution water / acetonitrile
- purity% l 1 corresponds to the purity of the product obtained after elution water / acetonitrile
- Time Ret2 corresponds to the retention time when eluting water / methanol
- purity% 2 corresponds to the purity of the product obtained after elution water / methanol.
- the neosynthesized and unpurified peptides were tritiated by catalytic saturation according to the procedure described in T ⁇ th G et al. (1997 Methods Mol Biol Vol 73, pp: 219-30).
- the tritiated gaseous dihydrogen gas 3 H 2 used is obtained from Technobexport, ( Russian) and contains a tritium content greater than or equal to 98%.
- the radioactivity of the crude peptides was measured using a TRI-CARB 2100TR scintillation counter in a scintillant composed of a toluene-Triton X-100 mixture.
- the measurement of the radioactivity was approximately 10OmCi (3.7 GBq)
- the tritiated peptides were purified by HPLC using a Grace Vydac 218TP54 C18 column, and detection of the scintillation fluid was performed on a Canberra Packard Radiomatic 505TR Flow Radiochromatography detector using Ultima-Flo M scintillant. Specific activity tritiated purified peptides were measured by HPLC using a standard curve. The specific activity obtained was between about 30.0 Ci mmol- 1 and
- the iodination of the peptides can be carried out according to several protocols known to those skilled in the art.
- the principle of protein iodination is based on the conversion of IT (NaI) to I + or I 3 " in the presence of oxidizing agents such as chloramine-T, iodogen (1,3,4,6-tetrachloro) - 3 ⁇ , 6 ⁇ -diphenyl-glycoluril), the JV-chloro-benzenesulfonamide or the lactoperoxidase I + or I 3 " are reactive species that attack the aromatic ring tyrosines meta position as described in" Antibodies: a laboratory manual " E. Harlow and D. Lane, CoId Spring Harbor Laboratory Press, 1988 pp. 324 - 339.
- radioactive iodine is used as Na 125 I in a basic solution at about 1 mCi (37 MBq) / 10 ⁇ L IODINE-125 (Amersham, IMS30).
- Stabilization solution (10% sodium thiosulfate + 0.1N NaOH) • IODO-BEAD TM (PIERCE): grafted with an oxidizing agent (N-chlorobenzenesulfonamide)
- the peptides are added to the solution (between 1 to 100 ⁇ g of peptide)
- the fractions of the column are collected, and the radioactivity of each of the fractions is measured, using a scintillation counter.
- Labeling buffer 25mM ammonium acetate buffer pH 5.3
- 3rd step co-elution of the fraction F1 of the ligand labeled with TI125 and the fraction "monoiodée"
- Example 4 Specificity of peptides: measurement of labeled peptide binding / extracellular portion of IRAP.
- the incubations were performed in 24-well plates in a final volume of 300 ⁇ L comprising 100 ⁇ l of the extracellular portion of IRAP, 50 ⁇ l of an EDTA / 1,10-phenanthroline mixture with a final concentration of 500 ⁇ M of EDTA and 100 ⁇ M of 1,10-phenanthroline, and either 50 ⁇ l of binding buffer, or 50 ⁇ l of binding buffer containing the unlabeled peptides for the competition tests.
- 50 ⁇ l of labeled peptides were added at a final concentration of 0.5 to 0.8 nM for the saturation tests, ie at a concentration of 3nM for the other tests.
- Incubation was performed at 37 ° C, at varying times (kinetics) up to 60 min.
- the radioactivity was then measured using a scintillation counter in the presence of ad hoc scintillation.
- the peptides were then separated from the serum by filtration gel and incubated at concentrations ranging from 0.1 nM to 1 .mu.M with the extracellular domain of IRAP purified in the presence of [125 I] - AnglV (0.1 - 1 nM) or [ 125 I] -NiE-AnglV (0.1 - 1 nM) and peptidase inhibitors and proteases.
- the stability of the peptides in the serum sample is then measured indirectly by measuring the competition of the I-labeled peptides with the binding of [I] -AngIV or [I] -Nle-AnglV to the extracellular domain of IRAP (see A. Lukaszuk et al., Chem Chem 51, 2291-2226, 2008).
- Example 6 IRAP RIA
- the assay of the circulating extracellular portion of IRAP (extIRAPc) uses an immunoradiometric method.
- the circulating extracellular portion of IRAP present in samples from patients where the standards is recognized by a monoclonal antibody (Mab) specific for the extracellular portion of IRAP, said monoclonal antibody being bound to the inner surface of the polystyrene tubes.
- Mob monoclonal antibody
- peptide * having a high affinity for extIRAPc induces the formation of a solid phase-bound sandwich complex (tube): Mab-extIRAPc - peptide * .
- the peptide fraction * not bound to the solid phase is removed by suction and washing.
- the formation of the complex is only realized in the presence of extIRAPc, the radioactivity related to the solid phase (tube) is directly proportional to the concentration of extIRAPc in the sample.
- a calibration curve makes it possible to determine, by interpolation, the concentration of extIRAPc of the samples to be assayed.
- the assay can be performed on human serum. If the assay is performed within 24 hours of collection, samples may be stored at 2-8 ° C. Otherwise, they must be aliquoted and frozen at -20 ° C. or at lower temperatures for a maximum of five months. If the samples have been frozen, wait until they are completely thawed and homogenize them before the assay. Avoid repeated freeze / thaw cycles.
- DILUTION OF THE WASH PAD Add 900 mL of distilled water to 100 mL of concentrated wash buffer. Avoid foaming, (wash buffer: PBS, 0.1% albumin, pH 7.4).
- ASSAY PROTOCOL Prior to use, coated tubes, standards, control sera and test sera are placed at room temperature (18-25 ° C) for at least 30 minutes; then their contents are mixed with the Vortex. It is recommended to run the assay in duplicate for both standards, control sera and samples. Carefully observe the order of use of the reagents: 1. Pipette 50 ⁇ L of each sample (standard, control serum and sample) and deposit as many tubes coated with the Mabs as samples taken, and in as many samples. uncoated tubes as samples taken.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10728786A EP2432800A2 (fr) | 2009-05-20 | 2010-05-19 | Peptides marques et leur utilisation pour le dosage d'irap circulant |
CA2762525A CA2762525A1 (fr) | 2009-05-20 | 2010-05-19 | Peptides marques et leur utilisation pour le dosage d'irap circulant |
JP2012511327A JP2012527437A (ja) | 2009-05-20 | 2010-05-19 | 標識ペプチド及び循環性irapのアッセイのためのその使用 |
US13/321,576 US20120115163A1 (en) | 2009-05-20 | 2010-05-19 | Marked peptides and use thereof for assaying circulating irap |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0953392A FR2945808B1 (fr) | 2009-05-20 | 2009-05-20 | Peptides marques et leur utilisation pour le dosage d'irap circulant |
FR09/53392 | 2009-05-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010133806A2 true WO2010133806A2 (fr) | 2010-11-25 |
WO2010133806A3 WO2010133806A3 (fr) | 2011-03-03 |
Family
ID=41647165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2010/050967 WO2010133806A2 (fr) | 2009-05-20 | 2010-05-19 | Peptides marques et leur utilisation pour le dosage d'irap circulant |
Country Status (6)
Country | Link |
---|---|
US (1) | US20120115163A1 (fr) |
EP (1) | EP2432800A2 (fr) |
JP (1) | JP2012527437A (fr) |
CA (1) | CA2762525A1 (fr) |
FR (1) | FR2945808B1 (fr) |
WO (1) | WO2010133806A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6734258B2 (ja) * | 2015-03-04 | 2020-08-05 | 栄研化学株式会社 | オキシトシンの高感度測定法 |
CN115212322B (zh) * | 2022-06-01 | 2024-01-16 | 原子高科股份有限公司 | 一种用于放射性药物制备的冻干药盒及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005038462A1 (fr) | 2003-10-21 | 2005-04-28 | Suntory Limited | Methode d'evaluation pronostique du carcinome mettant en oeuvre un anticorps anti-lap-p |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753875A (en) * | 1981-11-02 | 1988-06-28 | Ryan James W | Method for assaying proteases with tagged proteinaceous inhibitors |
US7473531B1 (en) * | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
EP1938104A2 (fr) * | 2005-10-17 | 2008-07-02 | Institute for Systems Biology | Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation |
WO2007140906A1 (fr) * | 2006-06-07 | 2007-12-13 | Bayer Healthcare Ag | Utilisation de la leucyl/cystinyl aminopeptidase (lnpep) en tant que cible thérapeutique ou diagnostique |
-
2009
- 2009-05-20 FR FR0953392A patent/FR2945808B1/fr active Active
-
2010
- 2010-05-19 CA CA2762525A patent/CA2762525A1/fr not_active Abandoned
- 2010-05-19 EP EP10728786A patent/EP2432800A2/fr not_active Withdrawn
- 2010-05-19 US US13/321,576 patent/US20120115163A1/en not_active Abandoned
- 2010-05-19 JP JP2012511327A patent/JP2012527437A/ja active Pending
- 2010-05-19 WO PCT/FR2010/050967 patent/WO2010133806A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005038462A1 (fr) | 2003-10-21 | 2005-04-28 | Suntory Limited | Methode d'evaluation pronostique du carcinome mettant en oeuvre un anticorps anti-lap-p |
Non-Patent Citations (16)
Title |
---|
A. LUKASZUK ET AL., MED CHEM., vol. 51, 2008, pages 2291 - 2296 |
ALBISTON, A. L. ET AL., J BIOL CHEM, vol. 276, no. 52, 2001, pages 48623 - 48626 |
ALBISTON, A. L. ET AL., PHARMACOL THER, vol. 116, no. 3, 2007, pages 417 - 427 |
DEMAEGDT ET AL., BIOCHEM. PHARMACOL., vol. 68, 2004, pages 885 - 892 |
HOTODA, N. ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 293, no. 2, 2002, pages 800 - 805 |
ITO, N. ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 314, no. 4, 2004, pages 1008 - 1013 |
KELLER, S. R. ET AL., J BIOL CHEM, vol. 270, no. 40, 1995, pages 23612 - 23618 |
KONDO C. ET AL., INT J. CANCER, vol. 118, 2006, pages 1390 - 1394 |
LUKASZUK ET AL., J. MED. CHEM., vol. 51, 2008, pages 2291 - 2296 |
MATSUMOTO, H. ET AL., EUR J BIOCHEM, vol. 267, no. 1, 2000, pages 46 - 52 |
MIZUTANI, S.; YOSHINO, M.; OYA, M., CLIN BIOCHEM, vol. 9, no. 1, 1976, pages 16 - 18 |
NARUKI, M., PEPTIDES, vol. 17, no. 2, 1996, pages 257 - 261 |
ROGI, T. ET AL., J BIOL CHEM, vol. 271, no. 1, 1996, pages 56 - 61 |
TÔTH G ET AL., METHODS MOL BIOL., vol. 73, 1997, pages 219 - 30 |
TSUJIMOTO, M.; MIZUTANI, S.; ADACHI, H.; KIMURA, M.; NA- KAZATO, H.; TOMODA, Y., ARCH BIOCHEM BIOPHYS, vol. 292, no. 2, 1992, pages 388 - 392 |
WALLIS, M. G. ET AL., AM J PHYSIOL ENDOCRINOL METAB, vol. 293, no. 4, 2007, pages E1092 - 1102 |
Also Published As
Publication number | Publication date |
---|---|
JP2012527437A (ja) | 2012-11-08 |
WO2010133806A3 (fr) | 2011-03-03 |
FR2945808B1 (fr) | 2013-12-27 |
FR2945808A1 (fr) | 2010-11-26 |
EP2432800A2 (fr) | 2012-03-28 |
CA2762525A1 (fr) | 2010-11-25 |
US20120115163A1 (en) | 2012-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brownell et al. | Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ | |
US20180118786A1 (en) | NOVEL lNHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA) | |
CN102741269A (zh) | Gadd45β靶向剂 | |
EP0466565B1 (fr) | Trousse pour le dosage spécifique de l'angiotensine II | |
Büchold et al. | New cis‐Configured Aziridine‐2‐carboxylates as Aspartic Acid Protease Inhibitors | |
JP2022522414A (ja) | 生存標的キメラ分子 | |
WO2015138532A2 (fr) | Méthodes de traitement de la fibrose rénale | |
CN102066416A (zh) | 肽、拟肽及其衍生物、它们的生产方法以及它们用于制备治疗和/或预防活性的药物组合物的用途 | |
FR2835255A1 (fr) | Test pour identifier des inhibiteurs de beta-secretases, procede de criblage de ces inhibiteurs, et nouveaux inhibiteurs de beta-secretases pour leur utilisation dans le traitement de la maladie d'alzheimer | |
RU2011131071A (ru) | Диагностика и лечение рака с помощью антитела против lgr7 | |
EP3666901A1 (fr) | Procédés de mesure de l'activité du facteur d et de la puissance d'inhibiteurs du facteur d | |
WO2010133806A2 (fr) | Peptides marques et leur utilisation pour le dosage d'irap circulant | |
CN115244401A (zh) | 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3 | |
Santos et al. | Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity | |
EP3097124B1 (fr) | Moyens et procédés de détection de malt1 activé | |
CN104395750A (zh) | 测量血液样品中蛋白水解级联的肽降解产物的方法 | |
FR2894584A1 (fr) | Nouveaux peptides et leurs applications biologiques | |
CA2405183C (fr) | Utilisation d'un reste pya-(z)x-pnf a des fins de detection, identification et/ou dosage par proteases ou peptidases par fluorescence | |
Brückner et al. | Capillary electrophoretic study of the degradation pathways and kinetics of the aspartyl model tetrapeptide Gly-Phe-Asp-GlyOH in alkaline solution | |
EP2702167B1 (fr) | Méthodes de diagnostic et de pronostic du myélome multiple, par détermination de l'expression de gadd45beta | |
US20220288156A1 (en) | Treatment | |
EP0345100A1 (fr) | Préparation de récepteurs du PAF et méthode de dosage du PAF | |
FR2664287A1 (fr) | Nouveau polypeptide presentant une activite enzymatique, et gene codant pour ce polypeptide. | |
FR2652901A1 (fr) | Complexes biologiques a base de nucleosomes, et leurs applications, notamment dans le domaine du diagnostic in vitro du lupus erythemateux dissemine (led). | |
WO2013086162A1 (fr) | Composés radioiodables de modulation de l'enzyme 2 de conversion de l'angiotensine (ace-2), leur préparation, et procédés pour leur utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10728786 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2762525 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012511327 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010728786 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010728786 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13321576 Country of ref document: US |